Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Clade Therapeutics Announces the Acquisition of Gadeta B.V.
Details : The acquisition will provide Clade with preclinical cell therapy programs, g/d TCR discovery engine and a suite of cell enhancement to improve anti-tumor activity of cell therapies.
Product Name : GDT002
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 10, 2023
Lead Product(s) : GDT002
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gadeta to Present Data on Tumor-Specific Cell Therapies at Leading Scientific Conferences
Details : GDT002 has a potent anti-tumor activity across a broad spectrum of solid and liquid tumor types as well as to discuss the data behind our decision to select ovarian cancer as an indication to explore the clinical effect of GDT002 against solid tumors.
Product Name : GDT002
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 28, 2022
Lead Product(s) : GDT002
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
First Patient Dosed with Gadeta's Gamma Delta TCR Cell Therapy
Details : The multicenter phase 1/2 study in collaboration with the Dana-Farber Cancer Institute, Mass General Brigham Cancer Care and Beth Israel Deaconess Medical Center, is evaluating safety, tolerability and preliminary efficacy of GDT-002 for the treatment of...
Product Name : GDT002
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 07, 2021
Reset All
